Senores Pharmaceuticals Limited has informed the Exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible ....

Date: July 27, 2026 To, To, SBrS. EG eLnimeriatle Md a nager SNra. tGioennearla Slt Mocakn aEgxecrh ange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex MBSuEm Sbcarii p– 4C0o0d e0:0 514 4319 BNaSnEd Sryam (Eb)o, lM: SuEmNbOaiR –E 4S 00 051 Sub.: Submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible equity warrants, for the quarter ended on June 30, 2026 Dear Sir/Madam, Pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD- 2/CIR/P/2024/185 dated December 31, 2024 and SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, please find enclosed herewith the statement of deviation(s) or variation(s) in utilisation of funds raised through preferential issue of 11,70,000 convertible equity warrants by the Company, for the quarter ended June 30, 2026. We hereby confirm that there has been no deviation(s) or variation(s) in the utilization of the funds raised through preferential issue of convertible equity warrants, for the abovementioned period, for the objects stated in the explanatory statement to the Notice of the Extra-ordinary General Meeting held on January 31, 2026. The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on July 27, 2026. This intimation is also being uploaded on the website of the Company i.e., www.senorespharma.com. You are requested to take the same on record. TFohra nSkeinnogr yeosu P. harmaceuticals Limited Deval Rajnikant Shah Whole Time Director & CFO DIN: 00332722 Enclosure Senores Pharmaceuticals Limited : As above 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 STATEMENT OF DEVIATION(S) / VARIATION(S) IN UTILISATION OF FUNDS RAISED THROUGH IPO, FOR THE QUARTER ENDED JUNE 30, 2026 Name of listed entity Mode of Fund Raising Senores Pharmaceuticals Limited Preferential Issue of 11,70,000 Convertible Equity Warrants each convertible into one Equity Share of face value ₹10/- (Rupees Ten only) each, at an exercise price of ₹ 812/- (Rupees Eight Hundred Date of Raising Funds and Twelve only) per Warrant Amount Raised March 28, 2026 Report filed for Quarter ended Rs. 95,00,40,000 Monitoring Agency June 30, 2026 Monitoring Agency Name, if applicable Not Applicable Is there a Deviation / Variation in use of Not Applicable funds raised If yes, whether the same is pursuant to change in terms of a contract or objects, Not Applicable which was approved by the shareholders If Yes, Date of shareholder Approval Explanation for the Deviation / Variation Not Applicable Comments of the Audit Committee after Not Applicable review No comments Comments of the auditors, if any No comments Objects for which funds have been raised and where there has been a deviation, in the following table Original Modified Original Modified Funds Amount Remark Object Object, if Allocation Allocatio n Utilized of s, if any any , if any Deviatio Variatio for the quarter accordin g to applicab le object Funding the Not 31,25,30,000 Not 6,84,00,000 No - working capital Applicable Applicable deviation requirements our Company Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Funding the Not 25,00,00,000 Not Nil No - product Applicable Applicable deviation development expenditure for the Company Investment in Not 15,00,00,000 Not 6,15,01,000 No - our Applicable Applicable deviation subsidiaries, by way of loan, to fund their working capital requirements General Not 23,75,10,000 Not 3,92,09,000 No - CToortpaol rate A pplicable 95,00,40,000 A pplicable 16,91,10,000 deviation Purpose Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised; or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or (c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc For Senores Pharmaceuticals Limited Deval Rajnikant Shah Whole Time Director & CFO DIN: 00332722 Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263